Table 2 Clinicopathologic characteristics and sites of recurrence of HR + /HER2-MBC patients by ESR1 mutation status
ESR1mut (n = 24; 63.2%) | ESR1wt (n = 14; 36.8%) | Total (n = 38) | p-value | |
|---|---|---|---|---|
Age at diagnosis, range (median) | ||||
27–80 (47.0) | 33–72 (54.5) | 27–80 (51.5) | 0.04 | |
ER, n (%) | ||||
Low | 0 | 2 (14.3) | 2 (5.3) | |
Positive | 24 (100) | 12 (85.7) | 36 (94.7) | |
PgR, n (%) | 0.59 | |||
Positive | 19 (79.2) | 10 (71.4) | 29 (76.3) | |
Negative | 5 (20.8) | 4 (28.6) | 9 (23.7) | |
HER2, n (%) | 0.20 | |||
Low | 17 (70.8) | 7 (50.0) | 24 (63.2) | |
Negative | 7 (29.2) | 7 (50.0) | 14 (36.8) | |
Site of recurrence after disease progression (biopsy site), n (%) | 0.99 | |||
Liver | 12 (50.0) | 7 (50.0) | 19 (50.0) | |
Contralateral breast | 2 (8.3) | 2 (14.3) | 4 (10.5) | |
Lymph node | 3 (12.5) | 1 (7.1) | 4 (10.5) | |
Lung | 2 (8.3) | 1 (7.1) | 3 (7.9) | |
Bone | 2 (8.3) | 1 (7.1) | 3 (7.9) | |
Other | 3 (12.5) | 2 (14.3) | 5 (13.2) | |
Sites of recurrence during the overall patients history, n (%) | 0.71 | |||
Liver | 12 (50.0) | 8 (57.1) | 20 (52.6) | |
Contralateral breast | 2 (8.3) | 2 (14.3) | 4 (10.5) | |
Lymph node | 16 (66.7) | 8 (57.1) | 24 (63.2) | |
Lung | 8 (33.3) | 1 (7.1) | 9 (23.7) | |
Bone | 15 (62.5) | 9 (64.3) | 24 (63.2) | |
Other | 5 (20.8) | 3 (21.4) | 8 (21.1) | |